收藏切换
Recent development in the treatment of chronic obstructive pulmonary disease with phosphodiesterase 4 inhibitors
收藏切换
Yujie SUN1, 2, Fenghua GU1, 2, *
World Clinical Drug | 2022, 43(4) : 480 - 484
Less
收藏切换
World Clinical Drug | 2022, 43(4): 480-484
• Review •
Recent development in the treatment of chronic obstructive pulmonary disease with phosphodiesterase 4 inhibitors
Full
Yujie SUN1, 2, Fenghua GU1, 2, *
Affiliations
  • 1.State Key Laboratory of & New Drug Pharmaceutical Process, China State Institute of Pharmaceutical Industry, Shanghai 200437, China
  • 2.Shanghai Technical Service Platform for Biological Material Druggability Evaluation, Shanghai 200437, China
Published: 2022-04-10 doi: 10.13683/j.wph.2022.04.021
Outline
收藏切换

Chronic obstructive pulmonary disease (COPD) is a chronic bronchitis and/or emphysema disease characterized by airflow obstruction, and the morbidity and mortality are increasing year by year. Although there are many kinds of drugs for the treatment of COPD, the clinical needs of patients with COPD are still unmet. In recent years, phosphodiesterase 4 inhibitor (PDE4I) has become a research hotspot. This article reviewed the latest research progress of PDE4I, in order to provide reference for the development of clinical new drugs.

phosphodiesterase 4 inhibitor  /  chronic obstructive pulmonary disease  /  research progress
孙玉杰, 顾丰华. 磷酸二酯酶-4抑制剂治疗慢性阻塞性肺疾病最新研究进展. 世界临床药物, 2022 , 43 (4) : 480 -484 . DOI: 10.13683/j.wph.2022.04.021
Yujie SUN, Fenghua GU. Recent development in the treatment of chronic obstructive pulmonary disease with phosphodiesterase 4 inhibitors[J]. World Clinical Drug, 2022 , 43 (4) : 480 -484 . DOI: 10.13683/j.wph.2022.04.021
Year 2022 volume 43 Issue 4
12
3
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.04.021
  • Receive Date:2021-10-18
  • Online Date:2026-11-19
  • Published:2022-04-10
Article Data
Affiliations
History
  • Received:2021-10-18
Affiliations
    1.State Key Laboratory of & New Drug Pharmaceutical Process, China State Institute of Pharmaceutical Industry, Shanghai 200437, China
    2.Shanghai Technical Service Platform for Biological Material Druggability Evaluation, Shanghai 200437, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.04.021
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT